Ionic Liquid Form Boosts Rifampicin Bioavailability
The modified antibiotic shows a 2.2-fold increase in bioavailability in animal models compared to the native compound.
Updated on Oct. 15, 2026 in Life Sciences
Live Poll
Should scientists prioritize reformulating existing medications to improve their effectiveness?
Researchers have synthesized an ionic liquid form of the antibiotic rifampicin to address its historically poor solubility and absorption. This research-stage development uses a 1:5 molar ratio of rifampicin to citric acid to improve delivery mechanisms.
Why it matters
The modification aims to solve the suboptimal oral bioavailability of rifampicin, a critical antibiotic, by chemically altering its structure to improve solubility. Improving the absorption profile of existing drugs is a key strategy in overcoming therapeutic limitations without requiring the development of entirely new compounds.
The new ionic liquid achieved a 20-fold increase in saturation solubility compared to the native drug. In A549 lung cells, the modified form demonstrated comparable cytotoxicity and cellular uptake to standard rifampicin.
The details
Researchers synthesized the material using a solvent-evaporation method, pairing rifampicin with citric acid at a 1:5 molar ratio to create an ionic liquid—a salt in a liquid state that can stabilize the drug molecule. They utilized a greenness-assisted high-performance liquid chromatography (HPLC) method—a technique used to separate and identify individual components in a mixture—to accurately measure serum levels. Unlike physical mixtures of the two ingredients, this specific ionic bond enables the observed solubility enhancements.
Timeline
October 15, 2026: The research results were published.
The Tech Race
This development follows the established precedent of utilizing pharmaceutical ionic liquids to bypass the solubility bottlenecks of legacy drugs. It reflects a broader shift toward re-engineering existing therapeutic agents to enhance their pharmacological performance.
This research-stage improvement in drug solubility is not yet available for clinical use or pharmaceutical manufacturing. Future adoption would depend on successful translation of these rabbit study results into human clinical trials and subsequent regulatory approval.
The takeaway
The research demonstrates a chemical pathway to increase the oral bioavailability of rifampicin by over twofold in animal models. Observers should track subsequent human safety studies to determine if these results translate into improved clinical outcomes for patients.
Further reading
For more on how material science is reshaping medical treatment, visit the Life Sciences section.
Source note: This article includes information reported by Nature.
Live Poll
Should scientists prioritize reformulating existing medications to improve their effectiveness?
